CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| ACOSOG-Z4032 | ACSOG | A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection Plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC); 3 cm or Smaller | Adult CIRB - Late Phase Emphasis | Completed |
| ACOSOG-Z4099 | ACSOG | A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)<br><br> | Adult CIRB - Late Phase Emphasis | Completed |
| ACOSOG-Z6051 | ACSOG | A Phase III Prospective Randomized Trial Comparing Laparoscopic-assisted Resection Versus Open Resection for Rectal Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| ACOSOG-Z9031 | ACSOG | A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients with Retroperitoneal Sarcomas (RPS) | Adult CIRB - Late Phase Emphasis | Completed |
| ACOSOG-Z1031 | ACSOG | A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily); Letrozole (2.5 mg); or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| ACOSOG-Z1041 | ACSOG | A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with HER-2 Positive Operable Breast Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| A221702 | Alliance | ARM: Axillary Reverse Mapping – A Prospective Trial To Study Rates Of Lymphedema And Regional Reccurence After Sentinel Lymph Node Biopsy And Sentinel Lymph Node Biopsy Followed By Axillary Lymph Node Dissection With And Without Axillary Reverse Mapping | Cancer Prevention and Control CIRB | Available to Open |
| A031201 | Alliance | Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide; Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| A212102 | Alliance | Blinded Reference Set for Multicancer Early Detection Blood Tests | Cancer Prevention and Control CIRB | Available to Open |
| EA9171 | Alliance | BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD | Adult CIRB - Late Phase Emphasis | Available to Open |